Purpose: Bone marrow (BM) is frequently used as a source of mesenchymal stem cells (MSCs) because they have a high potential for differentiation. However, it is unclear whether BMderived MSCs lead to better clinical and magnetic resonance imaging (MRI) outcomes postoperatively.
Introduction
Osteoarthritis (OA) is a progressively debilitating condition that causes cartilage erosion of the involved joint with pain and func tional impairment. Traditional methods to regenerate defects of articular cartilage include microfracture, multiple perforations, abrasions and mosaicplasty, the results of which are not satisfac tory 1, 2) . Autologous chondrocyte implantation (ACI) could be one method to regenerate an articular cartilage defect. However, ACI is not applicable to articular cartilage defects in OA because chondrocytes from patients suffering from OA have totally differ ent biological properties 3) . Additionally, for large articular carti lage defects in patients with OA, an alternative cell source should be found. As an alternative, mesenchymal stem cells (MSCs) can be used to regenerative articular cartilage defects 4) . MSCs can be isolated from a variety of sources, such as bone marrow (BM), adipose tissue, umbilical cord, amniotic fluid, dental pulp, sy novial tissue, peripheral blood and skeletal muscles. It , and SeonHeui Lee, RN, PhD . Furthermore, BM is frequently used as a source for MSCs be cause they are relatively easy to isolate and they have a high po tential for differentiation, even though it needs amount increases over several weeks in culture conditions for effective cellular dos age 6) . Although there have been many studies on adiposederived MSCs or adiposederived stromal vascular fraction 710) , few have assessed BMderived MSCs and the results have been inconclu sive. Previous studies have conducted a systematic review of the MSCs for the treatment of cartilage lesions 11, 12) ; however, evidence is insufficient due to the different location of cartilage defect, dif ferent cell sources, different etiology, and different MSC dosage. Few direct comparisons of clinical scores on knee outcome scales and magnetic resonance imaging (MRI) outcomes between the baseline and final followup have been conducted in patients with knee OA treated with BMderived MSCs. In addition, no meta analyses on this subject have been published.
This metaanalysis was performed to assess clinical and MRI outcomes after surgery in patients with knee OA treated with BMderived MSCs. It was hypothesized that BMderived MSCs would lead to better clinical outcomes and MRI outcomes on fi nal followup in these patients.
Materials and Methods

Data and Literature Sources
This study followed the Cochrane Review Methods. Multiple comprehensive databases, including MEDLINE (January 1, 1976 to September 30, 2017), EMBASE (January 1, 1985 to September 30, 2017), and the Cochrane Library (January 1, 1987 to Septem ber 30, 2017) were searched for studies of patients with knee OA treated with BMderived MSCs which used the following assess ments to compare clinical outcome: visual analog scale (VAS) for pain, Western Ontario McMaster Universities Arthritis Index (WOMAC), Lysholm score, Hospital for Special Surgery (HSS) score and range of motion (ROM). Selected studies also com pared MRI outcomes using the wholeorgan magnetic resonance imaging score (WORMS) and poor cartilage index (PCI). There was no language restriction, and filters of any kind were not ap plied for the strategy. The following keywords and their compre hensive combination and pertinent Medical Subject Headings (MeSH) were used to select the relevant articles: 'mesenchymal stem cells' OR 'mononuclear cells' OR 'bone marrowderived mesenchymal stem cell' OR 'bone marrow stromal cells' OR 'muscular skeletal disease' OR 'osteoarthritis. ' After the initial electronic search, relevant articles and their bib liographies were searched manually.
Study Selection
Based on the title and abstract, two reviewers independently selected the relevant studies for full review. The full text copy of each article was reviewed if the abstract did not provide enough data to make a decision. Studies were included in the meta analysis if they (1) assessed clinical outcomes, as determined by VAS for pain, WOMAC, Lysholm score, HSS score and ROM between the baseline and final followup, and MRI outcomes, as determined by WORMS and PCI between the baseline and final followup; (2) reported direct comparisons of surgical outcomes in patients with knee OA treated with intraarticular injections of BMderived MSCs; (3) included data on at least one of the following 7 parameters: VAS for pain, WOMAC, Lysholm score, HSS score, ROM, WORMS and PCI. For the overall functional outcome measure, we combined comparable scores from differ ent functional outcome tools when these tools scored disability: the higher the score, the greater the disability. Using the same method, we combined comparable scores of postoperative pain: the higher the score, the greater the pain. For WORMS, we re corded total WORMS score as assessed by cartilage thickness, signal intensity, and subchondral bone alteration and volume. The higher score values indicate more damage 13) . PCI was evalu ated using the mean T2 relaxation values sampled in 88 wellde fined regions of interest: values at 100 present the worst possible PCI, and those at 5 or below are considered healthy 14) ; (4) fully reported the number of patients in each group (baseline and final followup groups) and the means and standard deviations for the 7 parameters; and (5) used adequate statistical methods to com pare these parameters between groups. Studies were excluded if they (1) were not original articles; (2) were preclinical studies; (3) had missing or inadequate outcome data, such as standard deviations or ranges of values; and (4) used open surgery as the delivery method.
Data Extraction and Methodological Quality Assessment
Two reviewers independently recorded data from each study using a predefined data extraction form and resolved any differ ences by discussion. Variables recorded included those associated with surgical outcomes, such as VAS for pain, WOMAC, Lysholm score, HSS score, ROM, WORMS and PCI. Sample size and the mean and standard deviation of surgical outcomes in each group were also recorded. If these variables were not included in the articles, the standardized mean difference (SMD) was calculated from the pvalue and sample size.
Two reviewers independently assessed the methodological qual ity of the studies using interrupted time series analyses, as recom mended by the Cochrane Effective Practical and Organisation of Care Group. Each study was judged based on seven standard criteria to detect whether the intervention has an effect signifi cantly greater than the underlying secular trend. Any unresolved disagreements between reviewers were resolved by consensus or by consultation with a third investigator.
Data Synthesis and Analysis
The main outcomes of the metaanalysis were the SMD for overall clinical outcomes and MRI outcomes at the final follow up compared to the baseline values due to use of several different measurement tools, including VAS for pain, WOMAC, Lysholm score, HSS score, ROM, WORMS and PCI. For all comparisons, SMD and 95% confidence interval (CI) were calculated for con tinuous outcomes. Heterogeneity was determined by estimating the proportion of betweenstudy inconsistencies due to actual differences between studies, rather than differences due to ran dom error or chance, using the I 2 statistic, with values of 25%, 50%, and 75% considered low, moderate, and high heterogeneity, respectively. All statistical analyses were performed with RevMan ver. 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). The risks of bias (low, high, or unclear) were independently as sessed by two investigators. Subgroup analyses based on differ ences in the length of followup time were performed for pain scores in an attempt to explore a potential source of heteroge neity. As a result, two subgroups were created: followup more than 3 years and followup less than 3 years for pain scores. In addition, sensitivity analysis was conducted by excluding one of the eligible studies at a time; two studies with additional surgical procedures, such as cartilage treatment and osteotomy were in cluded 15, 16) . Pooling of data was feasible for only two outcomes of interest, i.e., pain and function scores.
Results
Identification of Studies
Details on study identification, inclusion, and exclusion are summarized in Fig. 1 . An electronic search yielded 270 studies in PubMed (MEDLINE), 309 in EMBASE and 3 in the Cochrane Library. Two additional publications were identified through manual searching. After removing 152 duplicates, 432 studies re mained; of these, 16 were excluded based on the abstract and full text article review, and an additional eight studies were excluded because they had unusable information or made inappropriate group comparisons. This eventually resulted in 8 studies that were included in the metaanalysis 1522) . 
Quality and Publication Bias of the Included Studies
The quality of the 8 studies included in the metaanalysis is summarized in Table 2 . Publication bias could not be assessed in these trials. Tests for funnel plot asymmetry are typically per formed only when at least 10 studies are included in the meta analysis. The metaanalysis included only 8 studies, and tests for asymmetry were not performed because these tests would not be able to differentiate asymmetry from chance.
Clinical Outcomes
Of the 8 studies, 7 compared pain score and included 133 pa tients assessed at the baseline and 133 at the final followup. The standardized mean was 1.38 points lower at the final follow up than at the baseline, and was significantly different between groups (95% CI, 0.89 to 1.87 points; p<0.001; I 2 =62%) (Fig. 2) . Two studies were assigned to the followup more than 3 years and five studies to the followup less than 3 years. The standard 
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ized mean in the more than 3 years of followup subgroup was 1.37 points lower at the final followup than at the baseline, and this difference was significant (95% CI, 0.33 to 2.40 points; p=0.01; I 2 =0%) (Fig. 2) . Likewise, the value in the less than 3 years of followup subgroup was 1.40 points lower at the final followup than at the baseline, and this difference was significant (95% CI, 0.80 to 1.99 points; p<0.001; I 2 =62%) (Fig. 2) . Six stud ies, including 142 patients assessed at the baseline and 142 at the final followup, reported function score. The standardized mean was 1.38 points lower at the final followup than at the baseline, and there was significant difference between groups (95% CI, 0.70 to 2.07 points; p<0.001; I 2 =83%) (Fig. 3) . The results of sensitiv ity analysis were not materially differentiated from those of the original analysis (Table 3) .
ROM and MRI Outcomes
Of the 8 studies, two compared ROM and included 24 patients assessed at the baseline and 24 at the final followup. The stan dardized mean in ROM was -4.41° lower at the baseline than at the final followup (95% CI, -13.05° to 4.24°; p=0.32; I 2 =98%) (Fig. 4) . Of the 8 studies, 4 compared MRI outcome and included 87 patients assessed with MRI at the baseline and 87 at the final Relat Res, Vol. 30, No. 3, Sep. 2018 211 followup. The standardized mean in MRI outcome was 0.62 lower at the final followup than at the baseline (95% CI, -0.16 to 1.40; p=0.12; I 2 =82%) (Fig. 5) .
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Discussion
The main findings of the current metaanalysis verified that there were no significant differences in the tested ROM and MRI outcomes when compared to the baseline values in patients treated with BMderived MSCs, whereas significant functional improvement and pain relief from the baseline were observed. BM stromal cells (BMSCs) can be used as a cell suspension expanded by culture or just as BM concentrate (BMC). There are some differences between these two procedures. Expanded BMSCs require twostep procedures in addition to legal approval for the clinical application and cost disadvantages. In contrast, BMC contains a mixture of different red blood cells, platelets, and leukocytes 23) . The adult MSC fraction is present in the leukocytes of the marrow, and their number is very limited compared to cultured MSCs. The marrow MSC and MSC precursors are ex tremely rare under normal conditions in human marrow before culture 24) . Some authors suggested that for favorable chondrogen esis, the optimal count of MSCs per cm 3 is an important factor 25) . However, there is no study of comparison between BMSC and BMC treatment. The treatment using expanded BMSCs might be difficult to manage from a legal point of view because it might be considered as a pharmacological agent administration. In Korea, unlike BMC, expanded BMSCs need additional approval by the Korean Food and Drug Administration for the treatment of OA. In spite of the complicated procedure, whether the in vitro expan 26) . BMderived MSCs administered into knee have ad hered to the surface of a damaged tissue, have differentiated into chondrocyte, and have expressed appropriate extracellular matrix protein, resulting in anatomic restoration on the damaged tissue with a significant relief of pain and disability 16, 21, 22) . Our meta analysis found that MRI outcomes did not show a significant dif ference from baseline despite the pain and functional advantages of injected BMderived MSCs. The similar results for the MRI outcomes were likely due to the cell dose injected into the knee and culture conditions, suggesting that an optimal cell density and purity could affect the cell expansion. According to the ani mal study of Agung et al. 27) , the ideal number of MSCs that are needed for the regeneration of cartilage is known to be 1×10 7 , and a few clinical studies report that 1×10 7 or more adult stem cells are ideal. Minimal criteria to define expanded multipotent human MSCs, as defined by the International Society for Cellular Therapy, include that they must be plasticadherent when main tained in standard culture conditions, express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11β, CD79α or CD19 and HLADR surface molecules, and they must be capable of differentiating into osteoblasts, adipocytes and chondroblasts in vitro 28) . Among our included articles, 6 stud ies 16, 1922) met the ideal number of MSCs, 2 studies 17, 18) used less than 1×10 7 MSCs. For MSC characterization, 2 studies 16, 21) did not describe the expression of CD. This could result in poor MRI outcomes than expected. In our metaanalysis, the tested ROM did not demonstrate any significant difference after BMderived MSCs administration. These results may also be partly explained by small patient samples, which can lead to reduced statistical power and less precision. Thus, the ROM outcomes of the cur rent metaanalysis could not be extended to all knee OA patients and further investigation through a future high volume study is necessary. This study had several limitations. Of the 8 studies, 3 were ob servational comparison studies, which are prone to both system atic and random errors, suggesting some inherent heterogeneity due to uncontrolled bias. In addition, the heterogeneity of the included studies could be explained by slight differences in other factors affecting clinical outcomes, including the use of a wide variety of cell dose and cell processing methods 29) as well as vari ability in functional and pain scores.
Conclusions
This metaanalysis found no significant differences in the tested ROM and MRI outcomes in patients treated with BMderived MSCs. On the other hand, they showed significant functional improvement and pain relief when compared with the baseline. Thus, BMderived MSCs appear to be a viable alternative for pa tients with knee OA, although longterm and highquality RCTs are needed to confirm the clinical benefits.
